SLC5A2 and Hepatic steatosis: This is in line with data from randomized trials of SGLT2 inhibitors in T2DM, which demonstrate similar reductions in liver enzymes independent of changes in weight and HbA1c.26 This may suggest a liver‐specific effect of SGLT2 inhibitors, although ALT has been shown to be a poor biomarker for hepatic steatosis.27